Financial Performance - The company's revenue for Q3 2022 reached ¥805,193,959.15, representing an increase of 8.18% compared to the same period last year[7] - The net profit attributable to shareholders for Q3 2022 was ¥15,462,621.60, a significant increase of 185.56% year-on-year[7] - Basic earnings per share for Q3 2022 were ¥0.0189, reflecting a growth of 456.60% compared to the previous year[7] - Total operating revenue for the current period reached ¥2,326,660,478.27, an increase from ¥2,224,300,970.63 in the previous period, representing a growth of approximately 4.6%[36] - Net profit for the current period was ¥121,283,831.87, a significant recovery from a net loss of ¥57,174,950.52 in the previous period[38] - Basic earnings per share for the current period improved to ¥0.0344, compared to a loss of ¥0.0317 per share in the previous period[38] - The company's total profit for the current period was ¥147,571,758.68, a recovery from a total loss of ¥36,220,327.39 in the previous period[38] Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥5,502,832,413.37, a decrease of 17.75% from the end of the previous year[7] - As of September 30, 2022, total assets amounted to ¥5,502,832,413.37, a decrease from ¥6,690,205,812.98 at the beginning of the year, representing a decline of approximately 17.7%[29] - Current assets decreased to ¥1,767,932,569.64 from ¥3,023,848,238.36, indicating a reduction of about 41.5%[29] - Total liabilities decreased to ¥3,794,910,476.50 from ¥5,104,155,707.98, reflecting a decline of approximately 25.7%[31] - The company's short-term borrowings significantly decreased from ¥1,274,371,644.23 to ¥99,850,000.00, a reduction of about 92.2%[31] - The company's total equity increased to ¥1,707,921,936.87 from ¥1,586,050,105.00, showing an increase of approximately 7.6%[31] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥97,923,313.84, down 53.27% year-on-year[7] - Cash flow from operating activities generated a net amount of ¥97,923,313.84, down from ¥209,549,867.80 in the previous period[42] - Cash inflow from operating activities totaled ¥2,332,736,027.28, compared to ¥2,184,543,218.48 in the previous period, reflecting an increase of approximately 6.8%[42] - Cash outflow from operating activities was ¥2,234,812,713.44, up from ¥1,974,993,350.68 in the previous period, indicating an increase of about 13.1%[42] - The net cash flow from financing activities was -1,037,090,264.24, a significant decrease compared to -43,062,707.58 from the previous period[45] - The net increase in cash and cash equivalents was -1,399,542,385.38, contrasting with an increase of 29,689,974.08 previously[45] - The ending balance of cash and cash equivalents was 591,558,206.67, down from 1,991,100,592.05 at the beginning of the period[45] Shareholder Information - Total number of common shareholders at the end of the reporting period was 32,374[20] - The largest shareholder, Beijing New Mileage Health Industry Group Co., Ltd., holds 25.30% of shares, totaling approximately 825.93 million shares[20] Company Changes - The company changed its name from "Hengkang Medical Group Co., LTD" to "New Journey Health Technology Group Co., LTD" effective September 26, 2022[26] Other Financial Metrics - The weighted average return on equity for Q3 2022 was 3.84%, an increase of 13.39% compared to the previous year[7] - The company received government subsidies totaling ¥6,655,762.71 during the quarter, contributing to its non-operating income[8] - Interest expenses increased by 58.29% to approximately $106.21 million compared to the same period last year[16] - Interest income surged by 1775.60% to approximately $8.28 million due to increased interest from restructured investments[16] - Investment income rose by 237.29% to approximately $11.57 million, attributed to debt forgiveness[16] - Credit impairment losses increased significantly by 2319.25% to approximately $38.91 million, reflecting recoveries from previous disposals[16] - Tax refunds received increased by 367.44% to approximately $2.73 million compared to the previous year[16] - Cash paid for operating activities rose by 31.40% to approximately $388.97 million, driven by restructuring costs[16] - Cash received from the disposal of subsidiaries amounted to approximately $42 million, marking a 100% increase[16] - Cash received from investment activities reached approximately $100 million, reflecting bank wealth management redemptions[16]

恒康医疗集团股份有限公司 2021 年年度报告全文 恒康医疗集团股份有限公司 2021 年年度报告 2022 年 04 月 1 恒康医疗集团股份有限公司 2021 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人林杨林、主管会计工作负责人刘军及会计机构负责人(会计主管 人员)刘军声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 亚太（集团）会计师事务所（特殊普通合伙）为本公司 2021 年度财务报告 的审计机构，对本公司 2021 年度财务报告出具了带有解释性说明的无保留意见 的审计报告（报告编号：亚会审字（2022）第 01520003 号），并出具《关于恒 康医疗集团股份有限公司 2021 年度财务报告非标准审计意见的专项说明（报告 编号：亚会专审字（2022）第 01520008 号）》。 本年度报告所涉及的公司未来发展战略、业绩规划等前瞻性陈述，属于未 来经营计划性事项，能否实现取决于市场状况变化等 ...

恒康医疗集团股份有限公司 2022 年第一季度报告全文 □ 是 √ 否 证券代码：002219 证券简称：*ST 恒康 公告编号：2022-060 恒康医疗集团股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中 财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 本报告期 上年同期 本报告期比上年同期增减 | --- | --- | --- | |-----------------------------------------------------|------------------|--------------------------| | | | | | 营 ...

恒康医疗集团股份有限公司 2021 年第三季度报告 证券代码：002219 证券简称：*ST 恒康 公告编号：2021-101 恒康医疗集团股份有限公司 2021 年第三季度报告 本公司管理人、本公司及董事会全体成员保证公告内容真实、准确和完整， 没有虚假记载、误导性陈述或者重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的 真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | --- | --- | --- | --- | --- | |------------------------------------------------------|------------------|-------------------------|------------------- ...

恒康医疗集团股份有限公司 2021 年半年度报告全文 恒康医疗集团股份有限公司 2021 年半年度报告 2021 年 08 月 1 恒康医疗集团股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 本公司管理人及公司董事会、监事会及董事、监事、高级管理人员保证半 年度报告内容的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏， 并承担个别和连带的法律责任。 公司负责人林杨林、主管会计工作负责人刘军及会计机构负责人(会计主管 人员)刘军声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本半年度报告所涉及的公司未来发展战略、业绩规划等前瞻性陈述，属于 未来经营计划性事项，能否实现取决于市场状况变化等多种因素，存在不确定 性，并不代表公司对未来年度的盈利预测，也不构成公司对投资者及相关人士 的实质性承诺。投资者及相关人士均应对此保持足够的风险认识，且应当理解 计划、预测与承诺之间的差异。敬请广大投资者注意投资风险！ 公司已在本报告中详细描述了可能存在的主要风险，请查阅本报告第三节 "管理层讨论与分析"章节相应内容。 目前法院已依法受理对公司重整 ...

恒康医疗集团股份有限公司 2021 年第一季度报告全文 恒康医疗集团股份有限公司 2021 年第一季度报告 2021 年 04 月 1 恒康医疗集团股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人林杨林、主管会计工作负责人刘军及会计机构负责人(会计主管 人员)王宁声明：保证季度报告中财务报表的真实、准确、完整。 2 恒康医疗集团股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | |-----------------------------------------------------|------------------|------------------|---------------------------| | □ 是 √ 否 | 本报告期 | ...

Business Model and Strategy - The company reported a significant shift from a single pharmaceutical manufacturing business to a dual-driven model focusing on medical services and pharmaceutical manufacturing, aligning with the "big health" industry strategy[21] - The company’s main business operations have expanded to include a variety of healthcare services, reflecting a strategic pivot in its business model[21] - The company aims to strengthen partnerships with top health service institutions and explore new high-end medical services[38] - The company is committed to deepening the development of unique Tibetan medicine products, aligning with national strategies for traditional medicine protection and innovation[39] - The company plans to implement the "hospital+" model to optimize resource allocation and address supply-demand issues in healthcare[108] - The company aims to increase drug sales revenue and brand influence through enhanced technology research and development and brand promotion efforts[132] - The company is exploring potential mergers and acquisitions to enhance its service offerings and market share[174] Financial Performance - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves for the fiscal year[6] - The company has received an unqualified audit report from Asia Pacific (Group) CPA, ensuring the accuracy and completeness of the financial statements[5] - The company has not disclosed specific future performance forecasts, emphasizing the uncertainty of achieving strategic goals due to market conditions[5] - The company’s financial report indicates a commitment to transparency and risk disclosure, with detailed descriptions of potential risks included in the report[5] - The company reported a basic and diluted earnings per share of -¥0.028, an improvement of 97.89% from -¥1.350 in 2019[23] - The company reported a net loss of 52.24 million CNY for 2020, with no cash dividends proposed for the year[116] - The company has not distributed cash dividends for the past three years due to continuous losses, with net losses of 2.52 billion CNY in 2019 and 1.42 billion CNY in 2018[119] - The company’s asset-liability ratio stands at 96.73%, indicating a high level of debt risk[112] Revenue and Expenses - The company's operating revenue for 2020 was ¥2,805,895,494.80, a decrease of 23.85% compared to ¥3,684,467,721.58 in 2019[23] - The company achieved total revenue of CNY 2.81 billion in 2020, a year-on-year decrease of 23.85%, with the medical services segment contributing CNY 2.37 billion, accounting for 84.62% of total revenue[56] - Service revenue accounted for 85.02% of total revenue, while industrial revenue made up 14.98%[64] - Medical service revenue was ¥2,374,437,844.47, down 2.32% from the previous year[64] - Gross profit margin for industrial revenue was 77.77%, while for service revenue it was 19.44%[68] - Sales expenses decreased by 8.95% to ¥223,099,998.35 due to pandemic-related restrictions[79] - Management expenses dropped by 43.31% to ¥337,739,590.33, primarily due to a reduced consolidation scope[79] - Financial expenses decreased by 64.53% to ¥139,922,838.34, attributed to lower interest expenses and exchange losses[79] Operational Metrics - The company operates 11 hospitals, including 1 tertiary hospital and 8 secondary or higher-level hospitals, focusing on regional medical centers[38] - The company expanded its academic promotion activities, conducting nearly 300 events in the second half of 2020 to enhance product recognition among doctors and patients[59] - The company added over 1,500 grassroots hospitals and more than 500 grade hospitals in 2020, effectively compensating for the decline in hospital medication usage due to the pandemic[59] - The hospital bed occupancy rate in China was 80.7% in 2019, indicating a high demand for inpatient services[45] - The number of patients served increased by 20% compared to the previous year, reaching 1.2 million patients[174] Market and Industry Trends - The healthcare industry in China is experiencing rapid growth, driven by an aging population and increasing healthcare awareness, with a significant rise in demand for medical services[40] - In 2019, the total healthcare expenditure in China reached CNY 65,195.9 billion, a year-on-year increase of 12.41%, with per capita healthcare expenditure at CNY 4,656.7[45] - The number of medical institutions in China increased to 1,007,545 by the end of 2019, with private hospitals growing by 6.90% year-on-year to 22,424[44] - The company is positioned to benefit from ongoing healthcare reforms aimed at addressing the challenges of accessibility and affordability in medical services[50] - The government has outlined a 10-year plan for healthcare reform, focusing on building a balanced and comprehensive medical insurance system by 2030[43] Risks and Challenges - The company is facing risks related to policy changes in the healthcare sector, which could impact its operations[112] - The company acknowledges the scarcity of high-quality medical talent as a significant risk factor affecting its service development[112] - The company is at risk of bankruptcy if its restructuring application is unsuccessful, which could lead to delisting[112] - The company faces a loan repayment obligation of ¥60 million to Huashang Bank, with ongoing litigation that may affect its financial position[154] - The company is involved in multiple lawsuits, including a claim for 91.03 million yuan related to performance compensation for 2017, which remains uncertain in its impact on future profits[145] Corporate Governance and Compliance - The company has established a comprehensive governance structure, with all board members present for the report's review, ensuring accountability[5] - The company has committed to ensuring the authenticity, accuracy, and completeness of restructuring application materials since January 20, 2016, and has strictly fulfilled this commitment[120] - The company has committed to strict compliance with relevant laws and regulations regarding share changes and has pledged to avoid any illegal trading activities[126] - The company has no reported penalties or rectifications during the reporting period, indicating compliance with regulations[155] Social Responsibility and Community Engagement - The company actively participated in COVID-19 pandemic response, deploying over 500 medical personnel to various prevention stations and screening over 300,000 individuals[192] - Total investment in poverty alleviation efforts amounted to approximately CNY 5.76 million, including CNY 5.23 million in funds and CNY 0.54 million in material donations[197] - The company helped 84 registered impoverished individuals to escape poverty during the reporting period[198] - The company provided free medical consultations and health education to rural communities through expert medical teams[197] - The company has maintained a commitment to environmental protection and improving product quality as part of its social responsibility efforts[192]

恒康医疗集团股份有限公司 2020 年第三季度报告全文 恒康医疗集团股份有限公司 2020 年第三季度报告 2020 年 10 月 1 恒康医疗集团股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人吕东明、主管会计工作负责人吕东明及会计机构负责人(会计主 管人员)王宁声明：保证季度报告中财务报表的真实、准确、完整。 2 恒康医疗集团股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------|------------------|-------------------------|------------------|--------------- ...

恒康医疗集团股份有限公司 2020 年半年度报告全文 恒康医疗集团股份有限公司 2020 年半年度报告 2020 年 08 月 1 恒康医疗集团股份有限公司 2020 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人吕东明、主管会计工作负责人吕东明及会计机构负责人(会计主 管人员)王宁声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本半年度报告所涉及的公司未来发展战略、业绩规划等前瞻性陈述，属于 未来经营计划性事项，能否实现取决于市场状况变化等多种因素，存在不确定 性，并不代表公司对未来年度的盈利预测，也不构成公司对投资者及相关人士 的实质性承诺。投资者及相关人士均应对此保持足够的风险认识，且应当理解 计划、预测与承诺之间的差异。敬请广大投资者注意投资风险！ 公司已在本报告中详细描述了可能存在的主要风险，请查阅本报告第四节 "经营情况讨论与分析"章节相应内容。 公司计划不派发现金红利，不送红股，不以 ...

恒康医疗集团股份有限公司 2019 年年度报告全文 恒康医疗集团股份有限公司 2019 年年度报告 2020 年 04 月 1 恒康医疗集团股份有限公司 2019 年年度报告全文 第一节重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人王伟、主管会计工作负责人王伟及会计机构负责人(会计主管人 员)王宁声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 亚太（集团）会计师事务所（特殊普通合伙）为本公司出具了带有解释性 说明的无保留意见的审计报告，本公司董事会、监事会对相关事项已有详细说 明，请投资者注意阅读。 本年度报告所涉及的公司未来发展战略、业绩规划等前瞻性陈述，属于未 来经营计划性事项，能否实现取决于市场状况变化等多种因素，存在不确定性， 并不代表公司对未来年度的盈利预测，也不构成公司对投资者及相关人士的实 质性承诺。投资者及相关人士均应对此保持足够的风险认识，且应当理解计划、 预测与承诺之间的差异。敬请广大投资者谨慎决策，注意投资 ...